VCAP-AMP-VECP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VCAP-AMP-VECP regimen refers to a regimen consisting of with vincristine, cyclophosphamide, doxorubicin (adriamycin), and prednisone (VCAP), doxorubicin (adriamycin), ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) used to treat human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL)[1]
Regimen
VVincristine
CCyclophosphamide
ADoxorubicin (Adriamycin)
PPrednisone
ADoxorubicin (Adriamycin)
MRanimustine (MCNU)
PPrednisone
VVindesine
EEtoposide
CCarboplatin
PPrednisone
Indications
- Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma (ATLL)[1]
References
- ↑ 1.0 1.1 Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y; et al. (2007). “VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801”. J Clin Oncol. 25 (34): 5458–64. doi:10.1200/JCO.2007.11.9958. PMID 17968021.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH